1 / 21

The mechanism of ADE

The mechanism of ADE. S58941418 陳俊良. Antibody-dependent enhancement (ADE). ADE has been proposed as an underlying pathogenic mechanism of DHF/ DSS. It often occurs in patients with second, heterotypic DENV infections or in infants with maternally transferred dengue immunity.

najila
Download Presentation

The mechanism of ADE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The mechanism of ADE S58941418 陳俊良

  2. Antibody-dependent enhancement (ADE) • ADE has been proposed as an underlying pathogenic mechanism of DHF/ DSS. • It often occurs in patients with second, heterotypic DENV infections or in infants with maternally transferred dengue immunity. • ADE occurs because preexisting subneutralizing antibodies • The infecting DENV form complexes that bind to Fc receptor-bearing cells • Leading to increased virus uptake and replication

  3. ADE of DENV-2 infection has also been demonstrated in • monkeys infused with a human dengue immune serum.

  4. ND/SK: bind to human and mouse IgG IBN: can’t bind to human and mouse IgG

  5. Antibody-dependent enhancement of infection by murine serum

  6. in vitro IgG 1A5:chimpanzee–human chimeric IgG1 mAbs C. The difference in ADE activities among the different DENV serotypes was probably due to sequence variations in the antibody- binding sites. B. Raji-1 (DC-SIGN) cells: has been shown to facilitate DENV infection by a mechanism different from ADE

  7. in vivo

  8. L-NIL, a specific inhibitor of iNOS

  9. Primary DHF Primary DHF 2nd DHF 2nd DHF

More Related